UCLA researchers in the Departments of Opthalmology have developed a xenobiotic-free manufacturing process to produce transplantable human limbal stem cells for use in treating limbal stem cell deficiency.
Limbal stem cell deficiency (LSCD) is a disorder characterized by the loss or dysfunctionality of limbal stem cells (LSCs) and its subsequent ability to regenerate the corneal epithelial surface. LSCD is characterized by persistent epithelial defects, conjunctivalization, neovascularization, scarring, and inflammation, all of which lead to corneal opacity, pain, photophobia, and ultimately blindness. Corneal transplantation is ineffective to treat severe to total LSCD because functional LSCs are not transplanted. The highest success rate of treating LSCD was achieved using single isolated LSCs cultured on 3T3 mouse fibroblasts feeder cells in a culture medium that contained fetal bovine serum (FBS). However, the presence of animal components in such xenobiotic culture systems poses a risk of transmitting animal diseases to human recipients after transplantation. There is a need for an effective and complete xenobiotic free culture system for culturing LSCs that minimizes the risk of cross-contamination and toxic effects when the LSCs are transplanted to the patient.
Researchers at UCLA developed a xenobiotic-free manufacturing process to produce transplantable human limbal stem cells for use in treating limbal stem cell deficiency. This method does not require the use of toxic compounds such as cholera toxin (to promote LSC proliferation) or DMSO (to enhance membrane permeability). The researchers have defined an optimal media and growth protocol for these cells.
Transplant of LSCs in patients with limbal stem cell deficiency
|European Patent Office||Published Application||3554487||10/23/2019||2017-431|
Additional Patent Pending
Limbal stem cells, cell culture, culture medium, xenobiotic-free, transplant, therapy, limbal stem cell deficiency, LSCD, cornea, opacity, blindness